Efficacy of lispro mix 25 BID versus glargine QD as starter insulin in patients with type 2 diabetes stratified by baseline HbA1c: subgroup analysis of a multi-national, randomized, open-label, parallel, controlled trial (DURABLE)

摘要

Objectve: According to the AACE guideline, patients with entry HbA1c >9% and symptoms can start insulin therapy, and according to the Chinese premixed insulin consensus, patients with HbA1c ≥9% who have inadequate glycemic control on two or more oral antihyperglycemic drugs (OADs) can start premixed insulin twice daily. This analysis compared the efficacy of lispro mix 75/25 (LM75/25) bid versus glargine QD by baseline HbA1c subgroup (<9% or ≥9%) to assess these two starter insulin strategies.